Research Reports

Prepared Highlights

2025年调整后每股收益为17.14美元，符合预期并高于初始指引（约16.25美元），同时进行了高于计划的投资以加速转型（CEO, CFO）
AEP期间会员增长约100万（20%），留存率同比提高超过500个基点；70%以上新销售来自竞争对手计划转换者，其中仅约12%来自竞争对手计划退出（CEO）
新销售中约70%来自4星及以上合同，近30%为回签会员，超过75%来自高终身价值渠道（同比提升近10个百分点）（CEO）
2026年预计个人MA会员增长约25%，新会员预计在2026年对企业整体具有增值作用（CEO）
预计2026年个人MA利润率（按星级标准化后）同比翻倍；但计入Stars不利因素后，初始指引假设个人MA利润率略低于盈亏平衡（CFO）
2026年Stars净不利因素（含个人和团体MA）约为35亿美元，其中考虑了合同多元化和供应商抵消（CFO）
2026年预计调整后每股收益至少为9美元，同比下降主要源于此前沟通的Bonus Year 2026 Stars不利因素（CFO）
2026年合并运营成本比率预计显著改善，驱动力为会员和收入增长的经营杠杆、战术成本削减及转型（CFO）
资本效率改善将抵消2024-2026年超过30亿美元的资本需求增长；尽管保费增长40%，法定资本要求增长不到20%（CFO）
债务与资本比率预计同比大致持平，公司致力于维持信用评级（CFO）
2025年保险分部福利比率为90.4%，略优于指引（CFO）
目前45%会员处于2026年4星及以上计划，但会员基数因增长而提高25%，且约30%新销售来自低于4星合同（CFO）

官方指引：

2026年全年调整后每股收益：至少9美元（CFO）

管理层引述：

“我们相信这是好的增长。超过70%的新销售来自竞争对手计划的转换者。平均而言，转换者具有更好的经济学。”（CEO）
“我们预期新会员在2026年对企业整体具有增值作用，但更重要的是，这将进一步推动我们实现2028年盈利潜力解锁的目标。”（CEO）
“我们始终以适当保守的方式制定最终指引。2026年的初始指引中，保守程度高于往常，以应对动态环境。”（CFO）
“尽管保费增长40%，我们的法定资本要求增长不到20%……这些资本效率改进将抵消超过30亿美元的资本需求增长。”（CFO）
“我们必须在每年的资金环境中制定MA福利策略。我们必须实现可持续的盈利和适当的回报，以为会员和患者提供卓越的健康结果和服务。”（CFO）

Prepared Metrics

Metric	Value	Speaker/Context
2025年调整后每股收益	17.14美元	CFO（符合预期）
2026年调整后每股收益指引	至少9美元	CFO（初始指引）
AEP会员增长	约100万（20%）	CEO
2026年个人MA会员增长预期	约25%	CEO
2025年保险分部福利比率	90.4%	CFO（略优于指引）
2026年Stars净不利因素	约35亿美元	CFO（含个人和团体MA）
2024-2026年保费增长	40%	CFO
2024-2026年法定资本要求增长	不到20%	CFO
资本效率抵消的资本需求增长	超过30亿美元	CFO（覆盖绝大部分2026年会员增长资金需求）

Q&A Batch (1-5 of 5)

Q1 — Stephen Baxter

Topic: 企业增值的盈利来源及新老MA承保利润率对比
Key points:
- 企业增值包含CenterWell收益：Pharmacy因新会员获得显著顺风，PCO患者增加，家庭健康量增长，均带来正面利润率影响。
- 2026年个人MA总利润率略低于盈亏平衡；新老会员利润率大致相似，但成因不同：老会员主要受Stars逆风影响（多数在不足4星合同），新会员Stars影响较小（70%在4星以上计划），但新会员收购成本仍高、MLR更高（因MRA较低、医疗成本可能更高）。
Mgmt stance: 中性；明确解释了利润率水平一致，但未表达乐观或悲观，强调竞争原因不给出细分。

Q2 — Justin Lake

Topic: 新会员利润率在3-5年内的演变路径及回到Stars第75百分位的净收益
Key points:
- 利润率提升路径：第1至第2年营销支出减半（正常化需约5年），之后MLR逐年改善，第2、3、4年持续，第5年基本正常。
- 其他改进因素：MRA随编码工作改善、医疗管理项目生效、会员逐步转入优质价值型合作伙伴。
- Stars第75百分位锚定的原因：适应行业政策变化，并给予规划弹性；具体净收益数字无法给出，但2028年目标已包含此假设（按75百分位计算）。
Mgmt stance: 看涨（关于利润率改善路径）；中性（关于Stars具体数字，强调可适应行业调整）。

Q3 — Ann Hynes

Topic: 2026年预期相比投资者日的变化及指引中的保守性
Key points:
- 与投资者日最大的差异是指引中嵌入的保守性：MRA保守、趋势假设整体打折扣。成本趋势类似于2025年（医疗成本中个位数高端，Rx低两位数），但2026年因缺少doc fix而略高。
- 2026年指引中的保守性体现在MRA、趋势假设以及整体额外打折，并非单一项目。
Mgmt stance: 谨慎（明确表示指引比正常年份更保守，并给出具体保守假设）。

Q4 — Benjamin Hendrix

Topic: D-SNP新会员数量、来源及价值型合作伙伴签约情况
Key points:
- 新D-SNP会员14万，同比增长18%，绝对数超预期但占比略低于预期。
- 未从竞争对手退出市场中获得份额。
- D-SNP会员大多来自HMO产品，进入时已签约价值型合作伙伴的比例高于整体业务块。

Q&A Batch (6-10 of 15)

Q6 — Scott Fidel

Topic: MA growth breakdown by PPO vs HMO
Key points:
- 25% overall MA growth cited, but company won't disclose PPO vs HMO growth rates.
- Management states new strategy aims for "reasonable margin" across all plans, not higher/lower margin splits.
- Unable to provide competitor-exit recapture percentage for PPO specifically.
Mgmt stance: Neutral — declines to give granular detail on plan-level metrics.

Q7 — Albert Rice

Topic: Transformation initiative timeline to 2028
Key points:
- Transformation to deliver $1.6B–$2B pretax improvement from 2025 to 2028.
- Member growth and CenterWell volume are "close to where we expected to be in 2028"; cost cutting "only just beginning" with significant pickup in 2027 and 2028.
- Group MA margin saw 500 bps pickup from recontracting (before Stars headwind); several hundred bps remaining.
Mgmt stance: Bullish — reaffirms 2028 target trajectory, cites upside from cost cuts, margin improvement in group MA, Medicaid J-curve, and CenterWell PCO clinics.

Q8 — Jason Cassorla

Topic: 2025 investment spend run rate and 2026 guidance approach
Key points:
- 2025 incremental investments estimated above $550M; no incremental investments currently contemplated for 2026.
- Tech investments are "a little bit higher" in 2026; no cutbacks.
- Star spend on a PMPM basis "down significantly" due to 25% membership growth; absolute dollar spend "fairly consistent" with 2025.
Mgmt stance: Neutral — cautious on additional investments but transparent about potential future decisions.

Q9 — Ryan Langston

Topic: Bounce-back member tenure and v28 impact
Key points:
- Bounce-back members (close to 30% of total) include several years of prior experience; more recent members are a larger percentage.
- v28 impact "around 160 basis points" — management confirms "nothing has changed there."
Mgmt stance: Neutral — no new disclosures beyond prior guidance.

Q10 — Elizabeth Anderson

Topic: EPS seasonality change and OEP outlook
Key points:
- Seasonality steeper than 2025 due to IRA and Stars headwind aggravating second-half operating leverage.
- Without Stars, trajectory "would be very similar" to prior year.
- OEP too early to assess; management sees "upside" from improved transactional NPS and benefit stability.
Mgmt stance: Bullish on OEP potential — cites member satisfaction and momentum.

Q&A Batch (11-15 of 15)

Q11 — Kevin Fischbeck

Topic: 2027 bid visibility and margin vs. membership trade-off
Key points:
- Member performance visibility by April, better by May; both early enough to adjust bids if needed, same as prior years.
- Management committed to Investor Day margin trajectory; first goal is long-term sustainable margin, not new member growth.
- Focus is on retention and margin, not new member growth.
Mgmt stance: Neutral — reaffirms existing commitments but acknowledges need to balance retention with margin discipline.

Q12 — Erin Wilson Wright

Topic: Rate notice exposure and statutory capital efficiency
Key points:
- Rate notice policy changes this year do not have the same variance as v28; most industry impact expected in a narrow band around the industry mean.
- Most capital efficiency work (redomestication) is done; further opportunities remain in reinsurance.
- Management expects to continue focusing on right capital level without excess drag.
Mgmt stance: Neutral — confident on rate notice impact being industry-wide, but still working through details; capital actions largely completed.

Q13 — Erin Wilson Wright (follow-up)

Topic: Rate notice details (clarification)
Key points:
- High-level message: policy changes this year do not have the same variance as v28; industry impact expected in a narrow band around the mean.
- Management feels confident everyone will be within margin of error around the industry mean.
Mgmt stance: Neutral — reiterates confidence in limited variance from rate notice.

Q14 — Matthew Gillmor

Topic: Value-based contracting mix and outlook
Key points:
- Membership split: ~1/3 full risk, ~1/3 other value-based, ~1/3 non-value-based or pay-for-performance.
- Influx of new members temporarily reduces value-based share at year start; builds back as members choose PCPs or claims-based attribution occurs.
- No significant concentration with any single provider; value-based partners want to expand.
Mgmt stance: Bullish — positive on value-based partner relationships and growth potential.

Q15 — Lance Wilkes

Topic: Value-based care MLR impact, capacity, and 2025 incremental investments
Key points:
- No change in financial performance contribution of value-based providers proportionally.
- In 2025, management provided significant support: took back Part D risk from value-based partners (continued into 2026) and mitigated Stars headwinds.
- Of incremental investments made in 2025, 90% were in medical costs.
Mgmt stance: Neutral — stable value-based performance; support actions ongoing; investment mix heavily medical cost-focused.